Enanta Pharma (ENTA) Tops Q3 EPS by 39c, beats revenue

Enanta Pharma (NASDAQ: ENTA) reported Q3 EPS of ($1.86), $0.39 better than the analyst estimate of ($2.25). Revenue for the quarter came in at $18.89 million versus the consensus estimate of $18.19 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits